NCT02311413View on ClinicalTrials.gov

A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

March 9, 2015

Primary Completion Date

July 18, 2018

Study Completion Date

July 18, 2018

Conditions
Cat AllergyCat Hypersensitivity
Interventions
DRUG

Cat-PAD

The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.

DRUG

Placebo

The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.

Trial Locations (1)

L8N 4A6

St. Joseph's Healthcare, Hamilton

All Listed Sponsors
collaborator

Circassia Limited

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02311413 - A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy | Biotech Hunter | Biotech Hunter